Acute generalized exanthematous pustulosis: A retrospective study of 51 cases in Taiwan

Lee, Yung-Yi; Chung, Wen‐Hung

doi:10.1016/j.dsi.2013.12.004

Cited by 7 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, none of the studied patients needed ICU admission, and no case of mortality was found. Similar to the findings of the present study, no mortality was reported among reported AGEP patients in the USA, Taiwan, Thailand, and France [7] , [8] , [9] , [10] .…”

Section: Discussionsupporting

confidence: 91%

Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital

Nili

Zarei

Ghamari

et al. 2020

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital

Nili

Zarei

Ghamari

et al. 2020

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

“… 95 , 96 Occasionally, dyskeratosis or necrosis of keratinocytes can be seen in AGEP. 97 In addition, systemic manifestation with fever and neutrophilia require attention to be paid to AGEP, and further short-term topical and corticosteroid treatment may be considered. 98 …”

Section: Acute Generalized Exanthematous Pustulosismentioning

confidence: 99%

Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies

Chen¹,

Wu²,

Ng³

et al. 2018

CMAR

Self Cite

115

View full text Add to dashboard Cite

With the increasing use of targeted anticancer drugs and immunotherapies, there have been a substantial number of reports concerning life-threatening severe cutaneous adverse reactions (SCARs), including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms, drug-induced hypersensitivity syndrome, and acute generalized exanthematous pustulosis. Although the potential risks and characteristics for targeted anticancer agent- and immunotherapy-induced SCAR were not well understood, these serious adverse reactions usually result in morbidity and sequela. As a treatment guideline for this devastating condition is still unavailable, prompt withdrawal of causative drugs is believed to be a priority of patient management. In this review, we outline distinct types of SCARs caused by targeted anticancer therapies and immunotherapies. Also, we discuss the clinical course, latency, concomitant medication, tolerability of rechallenge or alternatives, tumor response, and mortality associated with these devastating conditions. Imatinib, vemurafenib, and rituximab were the top three offending medications that most commonly caused SJS/TEN, while EGFR inhibitors were the group of drugs that most frequently induced SJS/TEN. For drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome and acute generalized exanthematous pustulosis, imatinib was also the most common offending drug. Additionally, we delineated 10 SCAR cases related to innovative immunotherapies, including PD1 and CTLA4 inhibitors. There was a wide range of latency periods: 5.5–91 days (median). Only eight of 16 reported patients with SCAR showed clinical responses. Targeted anticancer drugs and immunotherapies can lead to lethal SCAR (14 deceased patients were identified as suffering from SJS/TEN). The mortality rate of TEN was high: up to 52.4%. The information compiled herein will serve as a solid foundation to formulate ideas for early recognition of SCAR and to discontinue offending drugs for better management.

show abstract

“…Sir, Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse drug reaction, which presents with rapid onset of numerous sterile non-follicular pustules on edematous erythema, accompanied with fever and neutrophilia. 1 AGEP is primarily associated with drug use, mainly antibiotics and antifungal agents. 2 Here, we report a case of curcumin-induced AGEP.…”

Section: Curcumin-induced Acute Generalized Exanthematous Pustulosismentioning

confidence: 99%

Curcumin-induced acute generalized exanthematous pustulosis

Wu¹,

Yen²,

Wang³

et al. 2020

Indian J Dermatol Venereol Leprol

Self Cite

View full text Add to dashboard Cite

Acute generalized exanthematous pustulosis: A retrospective study of 51 cases in Taiwan

Cited by 7 publications

References 13 publications

Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital

Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital

Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies

Curcumin-induced acute generalized exanthematous pustulosis

Contact Info

Product

Resources

About